Blastic plasmacytoid dendritic cell neoplasm: The first report of two cases treated by 5-Azacytidine

European Journal of Haematology

Volumn 93, Issue 1, 2014, Pages 81-85

  Laribi, Kamel ^a   Denizon, Nathalie ^a   Ghnaya, Habib ^a   Atlassi, Mustapha ^a   Besançon, Anne ^a   Pineau Vincent, Fabienne ^a   Gaulard, Philippe ^b   Petrella, Tony ^c  

^a CENTRE HOSPITALIER DU MANS   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

5 Azacytidine; Blastic plasmacytoid dendritic cell neoplasm; BPDCN; Hematodermic neoplasm; PDC

Indexed keywords

AZACITIDINE; CD123 ANTIGEN; CD2 ASSOCIATED PROTEIN; CD4 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CD7 ANTIGEN; CD79A ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; HEMOGLOBIN; KI 67 ANTIGEN;

AGED; ARTICLE; BASOPHIL; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; CAUSE OF DEATH; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CYTOPENIA; DISEASE DURATION; EOSINOPHIL COUNT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; LUNG DISEASE; LYMPHOBLASTOID CELL; LYMPHOCYTE COUNT; MALE; MONOCYTE; MONOSOMY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; PAPULE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULMONARY SEPSIS; SEPSIS; SKIN BIOPSY; SKIN DEFECT; TREATMENT DURATION; VERY ELDERLY; HEMATOLOGIC NEOPLASMS; PATHOLOGY;

AGED; AGED, 80 AND OVER; AZACITIDINE; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE;

EID: 84902533458     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12294     Document Type: Article

References (26)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organisation (WHO) classification of myeloid neoplasm and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
2. Dalle S, Beylot-Barry M, Bagot M, et al. Blastic plasmocytoid dendritic cell neoplasm: is transpnantation the treatment of choice ?. Br J Dermatol 2010;162:74-9.
3. Borchiellini D, Ghibaudo N, Mounier N, Del Giudice P, Quinsat D, Ticchioni M, Perrin C, CardotLeccia N, Lacour JP. Blasticplasmacytoid dendritic cellneoplasm: a report of four cases and review of the literature. J Eur Acad Dermatol Venereol 2013;27:1176-81.
4. Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005;11:3604-8.
5. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphoma (agranular CD4 + CD56 hematodermic neoplasms). Am J ClinPathol 2005;123:662-75.
6. Assaf C, Gellrich S, Wittaker S, et al. CD56lymphoproliferative sordersof the skin: Amulticenter study of the cutaneous lymphoma Project Group of the EuropeenOrganisation for Research and Treatment of Cancer (EORTC). J ClinPathol 2007;60:981-9.
7. Herling M, Jones D. CD4+/CD56+Hematodermic tumor. The features of an evolving entity and its relationship to dendritic cells. Am J ClinPathol 2007;127:687-700
8. Feuillard J, Jacob M-C, Valensi F, et al. Clinical and biologic features of CD4 + CD56 + malignancies. Blood 2002;99:1556-63.
9. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. EfficacyofAzacytidine compared with that of conventional care reimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study. Lancet Oncol 2009;10:223-32
10. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacytidine prolongs overall survival compared with conventional care reimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J ClinOncol 2010;28:562-9
11. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of Azacytidine in patients with the myelodysplastic Syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-40.
12. Quintás-Cardama A, Santos FP, Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes.Nat Rev Clin Oncol 2010;7:433-44. Epub 2010 Jun 15. Review.
13. Rohon P, Vondrakova J, Jonasova A, Holzerova M, Jarosova M, Indrak K. Treatment of chronic myelomonocytic leukemia with 5-Azacytidine: case reports. Case Rep Hematol 2012;2012. Article ID 369086. doi:10.1155/2012/369086
14. Jones PA, Taylor SM, Wilson VL. Inhibition of DNA methylation of 5Azacytidine. Recent Results. Cancer 1983; 84: 202-11
15. Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacytidine after allogenic stem transplantation for acute leukaemia. Cancer 2009;115:1899-905.
16. Frikeche J, Clavert A, Delaunay J, et al. Impact of hypomethylating agent 5 Azacytidine on dendritic cellsfonction. Exp Hematol 2011;39:1056-63
17. Goodyear O, Agathanggelou A, Novitzky-Basso I, et al. Induction of a CD8+Tcellresponse to the MAGE cancer testis antigen by combined treatment with azacytidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010;116:1908-18.
18. Au WY, Wong KY, Wan TS, et al. A unique case of B cell lymphoma relapsing as CD4/CD56 blastic neoplasm. Leuk Lymphoma 2009;50:932-6.
19. Parlier V, van Melle G, Beris P, Schmidt PM, Tobler A, Haller E, Bellomo MJ. Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Prognostic significance of morphology and chromosome findings. Cancer Genet Cytogenet 1994;78:219-31.
20. Costa R, Abdullah H, Haq B, Shadduck RK, Latsko J, Zenati M, Atem FD, Rossetti JM, Sahovic EA, Lister J. Activity of Azacytidine in chronic myelomoocytic leukemia. Cancer 2011;117:2690-6
21. Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 2011;118:3824-31. doi: 10.1182/blood-2011-05-352039. Epub 2011 Aug 9
22. Merkel D, Filanovsky K, Gafter-Gvili A, et al. P. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine. A retrospective multicenter study. Am J Hematol 2013;88:130-4.
23. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer, update by the infectious diseases society of america. Clin Infect Dis 2010;2011:e56-93.
24. Lee JH, Lee KH, Kim DY, et al. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome. Leuk Res 2011;35:499-503.
25. Steensma DP. Hematopoietic growth factors in myelodysplastic syndromes. Semin Oncol 2011;38:635-47.
26. Stone RM. How I treat patients with myelodysplastic syndromes. Blood 2009;113:6296-303.